{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:07Z","timestamp":1790710147116,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-024-03453-z","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T04:10:25Z","timestamp":1734581425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Poor prognostic factors for relapse of interstitial lung disease in microscopic polyangiitis: the Japanese multicentre REVEAL cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Shogo","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayana","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Manabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Kadoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuneyasu","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Hiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"12","key":"3453_CR1","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.autrev.2010.07.009","volume":"9","author":"PM Villiger","year":"2010","unstructured":"Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev. 2010;9(12):812\u20139.","journal-title":"Autoimmun Rev"},{"issue":"6","key":"3453_CR2","doi-asserted-by":"publisher","first-page":"103100","DOI":"10.1016\/j.autrev.2022.103100","volume":"21","author":"BS Walker","year":"2022","unstructured":"Walker BS, Peterson LK, Koening C, White SK, Schmidt RL, Tebo AE. Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(6):103100.","journal-title":"Autoimmun Rev"},{"key":"3453_CR3","doi-asserted-by":"publisher","first-page":"102338","DOI":"10.1016\/j.jaut.2019.102338","volume":"106","author":"T Maillet","year":"2020","unstructured":"Maillet T, Goletto T, Beltramo G, Dupuy H, Jouneau S, Borie R, et al. Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor. J Autoimmun. 2020;106:102338.","journal-title":"J Autoimmun"},{"issue":"2","key":"3453_CR4","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar4550","volume":"16","author":"KE Sada","year":"2014","unstructured":"Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, et al. Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther. 2014;16(2):R101.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"3453_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3899\/jrheum.220123","volume":"49","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Kotani T, Kuwabara H, Suzuka T, Kiboshi T, Wada Y, et al. Association of M2 macrophages, Th2, and B cells with pathomechanism in microscopic polyangiitis complicated by interstitial lung disease. J Rheumatol. 2022;49(8):913\u201321.","journal-title":"J Rheumatol"},{"issue":"1","key":"3453_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13075-020-02234-8","volume":"22","author":"K Matsumoto","year":"2020","unstructured":"Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, et al. Longitudinal immune cell monitoring identified CD14. Arthritis Res Ther. 2020;22(1):145.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"3453_CR7","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/j.chest.2021.01.083","volume":"159","author":"H Hozumi","year":"2021","unstructured":"Hozumi H, Kono M, Hasegawa H, Yasui H, Suzuki Y, Karayama M, et al. Clinical significance of interstitial lung Disease and its Acute Exacerbation in Microscopic Polyangiitis. Chest. 2021;159(6):2334\u201345.","journal-title":"Chest"},{"issue":"2","key":"3453_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10067-022-06388-5","volume":"42","author":"K Yamaguchi","year":"2023","unstructured":"Yamaguchi K, Yamaguchi A, Ito M, Wakamatsu I, Itai M, Muto S, et al. Clinical differences among patients with myeloperoxidase-antineutrophil cytoplasmic antibody-positive interstitial lung disease. Clin Rheumatol. 2023;42(2):479\u201388.","journal-title":"Clin Rheumatol"},{"key":"3453_CR9","doi-asserted-by":"publisher","first-page":"1064307","DOI":"10.3389\/fphar.2023.1064307","volume":"14","author":"MJ Kim","year":"2023","unstructured":"Kim MJ, Lee D, Choe J, Song JW. Long-term clinical course and outcomes of patients with microscopic polyangiitis-associated interstitial lung disease. Front Pharmacol. 2023;14:1064307.","journal-title":"Front Pharmacol"},{"key":"3453_CR10","doi-asserted-by":"publisher","first-page":"106992","DOI":"10.1016\/j.rmed.2022.106992","volume":"203","author":"J Otsuka","year":"2022","unstructured":"Otsuka J, Yoshizawa S, Ikematsu Y, Kudo K, Osoreda H, Ishimatsu A, et al. Acute exacerbation in antineutrophil cytoplasmic antibody-associated interstitial lung disease: clinical features and risk factors. Respir Med. 2022;203:106992.","journal-title":"Respir Med"},{"issue":"1","key":"3453_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12890-021-01451-4","volume":"21","author":"X Sun","year":"2021","unstructured":"Sun X, Peng M, Zhang T, Li Z, Song L, Li M, et al. Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody. BMC Pulm Med. 2021;21(1):88.","journal-title":"BMC Pulm Med"},{"issue":"13","key":"3453_CR12","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.3390\/jcm11133835","volume":"11","author":"H Yamakawa","year":"2022","unstructured":"Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T, et al. Anti-inflammatory and\/or anti-fibrotic treatment of MPO-ANCA-Positive interstitial lung disease: a short review. J Clin Med. 2022;11(13):3835.","journal-title":"J Clin Med"},{"issue":"1","key":"3453_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13730-013-0074-1","volume":"3","author":"F Takahashi","year":"2014","unstructured":"Takahashi F, Miura E, Shibukawa K, Chinda J, Miyokawa N, Imamoto C, et al. Monitoring with serum SP-A, SP-D, and KL-6 in a patient with interstitial pneumonia complicated with ANCA-associated glomerulonephritis. CEN Case Rep. 2014;3(1):5\u20139.","journal-title":"CEN Case Rep"},{"issue":"10","key":"3453_CR14","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.1093\/rheumatology\/keab064","volume":"60","author":"S Matsuda","year":"2021","unstructured":"Matsuda S, Kotani T, Kuwabara H, Suzuka T, Kiboshi T, Fukui K, et al. CCL2 produced by CD68+\/CD163\u2009+\u2009macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease. Rheumatology (Oxford). 2021;60(10):4643\u201353.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"3453_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41584-021-00721-z","volume":"18","author":"F Luppi","year":"2022","unstructured":"Luppi F, Sebastiani M, Salvarani C, Bendstrup E, Manfredi A. Acute exacerbation of interstitial lung disease associated with rheumatic disease. Nat Rev Rheumatol. 2022;18(2):85\u201396.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"3453_CR16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1183\/09031936.06.00038806","volume":"28","author":"T Suda","year":"2006","unstructured":"Suda T, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Naito T, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28(5):1005\u201312.","journal-title":"Eur Respir J"},{"issue":"6","key":"3453_CR17","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/rheumatology\/kead444","volume":"63","author":"S Matsuda","year":"2024","unstructured":"Matsuda S, Kotani T, Okazaki A, Nishioka D, Watanabe R, Gon T, et al. Prediction model for respiratory-related mortality in microscopic polyangiitis with interstitial lung disease: multicenter REVEAL cohort study. Rheumatology (Oxford). 2024;63(6):1607\u201315.","journal-title":"Rheumatology (Oxford)"},{"key":"3453_CR18","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","DOI":"10.1002\/art.37715"},{"issue":"12","key":"3453_CR19","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1136\/ard.2008.101279","volume":"68","author":"C Mukhtyar","year":"2009","unstructured":"Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, et al. Modification and validation of the Birmingham Vasculitis Activity score (version 3). Ann Rheum Dis. 2009;68(12):1827\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"3453_CR20","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1136\/ard.2006.062711","volume":"66","author":"B Hellmich","year":"2007","unstructured":"Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and\/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66(5):605\u201317.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3453_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL, et al. The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Med (Baltim). 2011;90(1):19\u201327.","journal-title":"Med (Baltim)"},{"issue":"6","key":"3453_CR22","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3453_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjd.14882","volume":"176","author":"T Matsushita","year":"2017","unstructured":"Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, et al. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol. 2017;176(2):395\u2013402.","journal-title":"Br J Dermatol"},{"issue":"7","key":"3453_CR24","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3453_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","volume":"194","author":"HR Collard","year":"2016","unstructured":"Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265\u201375.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3453_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/s41598-021-81311-7","volume":"11","author":"S Matsuda","year":"2021","unstructured":"Matsuda S, Kotani T, Suzuka T, Kiboshi T, Fukui K, Wakama M, et al. Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease. Sci Rep. 2021;11(1):1490.","journal-title":"Sci Rep"},{"issue":"3","key":"3453_CR27","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"9","key":"3453_CR28","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3(9):e003132.","journal-title":"BMJ Open"},{"issue":"5","key":"3453_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3899\/jrheum.180778","volume":"46","author":"H Hozumi","year":"2019","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, et al. Efficacy of glucocorticoids and calcineurin inhibitors for Anti-aminoacyl-tRNA synthetase antibody-positive Polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis. J Rheumatol. 2019;46(5):509\u201317.","journal-title":"J Rheumatol"},{"issue":"2","key":"3453_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1055\/s-0034-1371527","volume":"35","author":"F Bonella","year":"2014","unstructured":"Bonella F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med. 2014;35(2):181\u2013200.","journal-title":"Semin Respir Crit Care Med"},{"issue":"12","key":"3453_CR31","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.rmed.2015.10.005","volume":"109","author":"T Okamoto","year":"2015","unstructured":"Okamoto T, Fujii M, Furusawa H, Tsuchiya K, Miyazaki Y, Inase N. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. Respir Med. 2015;109(12):1576\u201381.","journal-title":"Respir Med"},{"issue":"3","key":"3453_CR32","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1164\/ajrccm.165.3.2107134","volume":"165","author":"H Ohnishi","year":"2002","unstructured":"Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, et al. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med. 2002;165(3):378\u201381.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6 Pt 1","key":"3453_CR33","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1164\/ajrccm.152.6.8520747","volume":"152","author":"Y Honda","year":"1995","unstructured":"Honda Y, Kuroki Y, Matsuura E, Nagae H, Takahashi H, Akino T, et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med. 1995;152(6 Pt 1):1860\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"3453_CR34","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1080\/14397595.2021.1879346","volume":"31","author":"N Tanaka","year":"2021","unstructured":"Tanaka N, Nishimura K, Waki D, Kadoba K, Murabe H, Yokota T. Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease. Mod Rheumatol. 2021;31(6):1100\u20136.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"3453_CR35","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/rheumatology\/key420","volume":"58","author":"S Takanashi","year":"2019","unstructured":"Takanashi S, Nishina N, Nakazawa M, Kaneko Y, Takeuchi T. Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. Rheumatology (Oxford). 2019;58(6):1034\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"3453_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/resp.13988","volume":"26","author":"CJW Stock","year":"2021","unstructured":"Stock CJW, Hoyles RK, Daccord C, Kokosi M, Visca D, De Lauretis A, et al. Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression. Respirology. 2021;26(5):461\u20138.","journal-title":"Respirology"},{"issue":"6","key":"3453_CR37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/art.40815","volume":"71","author":"M Elhai","year":"2019","unstructured":"Elhai M, Hoffmann-Vold AM, Avouac J, Pezet S, Cauvet A, Leblond A, et al. Performance of candidate serum biomarkers for systemic sclerosis-Associated interstitial lung disease. Arthritis Rheumatol. 2019;71(6):972\u201382.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3453_CR38","doi-asserted-by":"publisher","first-page":"17616","DOI":"10.1038\/s41598-023-45027-0","volume":"13","author":"S Sakamoto","year":"2023","unstructured":"Sakamoto S, Suzuki A, Homma S, Usui Y, Shimizu H, Sekiya M, et al. Outcomes and prognosis of progressive pulmonary fibrosis in patients with antineutrophil cytoplasmic antibody-positive interstitial lung disease. Sci Rep. 2023;13(1):17616.","journal-title":"Sci Rep"},{"issue":"22","key":"3453_CR39","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"5","key":"3453_CR40","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","volume":"160","author":"T Petnak","year":"2021","unstructured":"Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: a systematic review and Meta-analysis. Chest. 2021;160(5):1751\u201363.","journal-title":"Chest"},{"issue":"3","key":"3453_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/1756-185X.14532","volume":"26","author":"Y Takakuwa","year":"2023","unstructured":"Takakuwa Y, Yamasaki Y, Matsushita H, Kiyokawa T, Mizushima M, Tonooka K, et al. Long-term survival, causes of death, and prognostic factors for mortality in patients with microscopic polyangiitis and those with anti-neutrophil cytoplasmic antibody-positive interstitial lung disease: a single-center retrospective study. Int J Rheum Dis. 2023;26(3):446\u201353.","journal-title":"Int J Rheum Dis"},{"issue":"4","key":"3453_CR42","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.21037\/jtd.2019.03.28","volume":"11","author":"A Manfredi","year":"2019","unstructured":"Manfredi A, Sebastiani M, Cerri S, Vacchi C, Tonelli R, Della Casa G, et al. Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. J Thorac Dis. 2019;11(4):1621\u20138.","journal-title":"J Thorac Dis"},{"issue":"5","key":"3453_CR43","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","volume":"60","author":"S Izuka","year":"2021","unstructured":"Izuka S, Yamashita H, Iba A, Takahashi Y, Kaneko H. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis. Rheumatology (Oxford). 2021;60(5):2348\u201354.","journal-title":"Rheumatology (Oxford)"},{"key":"3453_CR44","doi-asserted-by":"publisher","first-page":"107242","DOI":"10.1016\/j.rmed.2023.107242","volume":"212","author":"J Lee","year":"2023","unstructured":"Lee J, Kim K, Jo YS. Comparison of the diagnostic criteria for progressive pulmonary fibrosis in connective tissue disease related interstitial lung disease. Respir Med. 2023;212:107242.","journal-title":"Respir Med"},{"issue":"18","key":"3453_CR45","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing interstitial lung diseases. N Engl J Med. 2019;381(18):1718\u201327.","journal-title":"N Engl J Med"},{"issue":"3","key":"3453_CR46","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363(3):221\u201332.","journal-title":"N Engl J Med"},{"issue":"8","key":"3453_CR47","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1097\/RHU.0000000000000042","volume":"19","author":"R Cozmuta","year":"2013","unstructured":"Cozmuta R, Merkel PA, Fraenkel L. Variability in experts\u2019 opinions regarding risks and treatment choices in patients with antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol. 2013;19(8):426\u201331.","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"3453_CR48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/rheumatology\/kev286","volume":"55","author":"JH Schirmer","year":"2016","unstructured":"Schirmer JH, Wright MN, Vonthein R, Herrmann K, N\u00f6lle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford). 2016;55(1):71\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"3453_CR49","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"key":"3453_CR50","doi-asserted-by":"publisher","first-page":"175346662211409","DOI":"10.1177\/17534666221140974","volume":"16","author":"T Wu","year":"2022","unstructured":"Wu T, Zhang Y, Cen Z, Ying Y, Sun C, Lv C, et al. Clinical significance of acute exacerbation in interstitial lung disease with antineutrophil cytoplasmic antibody: an indicator of poor prognosis. Ther Adv Respir Dis. 2022;16:17534666221140974.","journal-title":"Ther Adv Respir Dis"},{"issue":"162","key":"3453_CR51","doi-asserted-by":"publisher","first-page":"210123","DOI":"10.1183\/16000617.0123-2021","volume":"30","author":"S Kadura","year":"2021","unstructured":"Kadura S, Raghu G. Antineutrophil cytoplasmic antibody-associated interstitial lung disease: a review. Eur Respir Rev. 2021;30(162):210123.","journal-title":"Eur Respir Rev"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03453-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03453-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T06:05:19Z","timestamp":1734588319000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03453-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3453"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03453-z","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and its amendments, and it was approved by the Osaka Medical College and the Faculties of Medicine Ethics Committee (approval no. 1529) and by the individual participating centres, including Kyoto University (approval no. R1540) and Osaka Metropolitan University (approval no. 2023-027). The Ethics Committee of Kyoto University waived the requirement for informed consent because of the anonymous nature of the data. Written informed consent was obtained from each patient at the other institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SM has received research grant from Japan Intractable Diseases Research Foundation and Promotion and Mutual Aid Corporation for Private Schools of Japan. TK has received payments for lectures from Abbvie, Bristol-Myers Squibb, Chugai, Eisai, Eli Lilly, Pfizer, and Boehringer Ingelheim. RW receives research grant from AbbVie and speaker\u2019s fee from Asahi Kasei, Chugai, Eli Lilly, GSK, and UCB Japan. RH received research grants from GSK, and speaker fee from Abbvie, Asahi Kasei, Brystol-Meyers Squibb, Eisai, Eli Lilly, GSK, Kissei, and Pfizer. MH received research grants and\/or speaker fee from Abbvie, Asahi Kasei, Astellas, Brystol Meyers, Chugai, Eisai, Daiichi Sankyo, Eli Lilly, Novartis Pharma, Tanabe Mitsubishi. TT received research grants and\/or speaker fee from Abbvie, Asahi Kasei, Astellas, Brystol-Meyers Squibb, Chugai, Eisai, Eli Lilly, Janssen pharma, Nihon Shinyaku, Mitsubishi-Tanabe, Takeda, and Pfizer. Other authors (AO, DN, YM, MS, TT, AM, KK, TY, WY) do not have any conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}